Top

Published in:

01-04-2013 | Case Report

Severe anaphylaxis caused by orally administered vancomycin to a patient with Clostridium difficile infection

Authors: D. Bossé, C. Lemire, J. Ruel, A. M. Cantin, F. Ménard, L. Valiquette

Published in: Infection | Issue 2/2013

Abstract

We report the first case of anaphylaxis to oral vancomycin in a cystic fibrosis patient with severe and relapsing Clostridium difficile infection (CDI) refractory to metronidazole. The patient’s colitis has been successfully treated with a combination of intravenous metronidazole and tigecycline.

Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31:431–55.PubMedCrossRef

Bauer MP, Kuijper EJ, van Dissel JT; European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect. 2009;15:1067–79.PubMedCrossRef

Gonzales M, Pepin J, Frost EH, et al. Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection. BMC Infect Dis. 2010;10:363.PubMedCrossRef

Osawa R, Kaka AS. Maculopapular rash induced by oral vancomycin. Clin Infect Dis. 2008;47:860–1.PubMedCrossRef

Bailey P, Gray H. An elderly woman with ‘Red Man Syndrome’ in association with oral vancomycin therapy: a case report. Cases J. 2008;1:111.PubMedCrossRef

Bergeron L, Boucher FD. Possible red-man syndrome associated with systemic absorption of oral vancomycin in a child with normal renal function. Ann Pharmacother. 1994;28:581–4.PubMed

Renz CL, Laroche D, Thurn JD, et al. Tryptase levels are not increased during vancomycin-induced anaphylactoid reactions. Anesthesiology. 1998;89:620–5.PubMedCrossRef

Ebo DG, Verheecke G, Bridts CH, Mertens CH, Stevens WJ. Perioperative anaphylaxis from locally applied rifamycin SV and latex. Br J Anaesth. 2006;96:738–41.PubMedCrossRef

Greenberg K, Espinosa J, Scali V. Anaphylaxis to topical bacitracin ointment. Am J Emerg Med. 2007;25:95–6.PubMedCrossRef

10.

Saryan JA, Dammin TC, Bouras AE. Anaphylaxis to topical bacitracin zinc ointment. Am J Emerg Med. 1998;16:512–3.PubMedCrossRef

11.

Scala E, Giani M, Pirrotta L, Guerra EC, De Pità O, Puddu P. Multiple drug allergy syndrome: severe anaphylactic reaction due to topical rifamycin SV in a patient with hypersensitivity to ciprofloxacin. Int J Dermatol. 2001;40:603–4.PubMedCrossRef

12.

Taylor SL, Hefle SL, Bindslev-Jensen C, et al. Factors affecting the determination of threshold doses for allergenic foods: how much is too much? J Allergy Clin Immunol. 2002;109:24–30.PubMedCrossRef

13.

Crespo JF, Pascual C, Dominguez C, Ojeda I, Muñoz FM, Esteban MM. Allergic reactions associated with airborne fish particles in IgE-mediated fish hypersensitive patients. Allergy. 1995;50:257–61.PubMedCrossRef

14.

Ramesh S. Antibiotic hypersensitivity in patients with CF. Clin Rev Allergy Immunol. 2002;23:123–41.PubMedCrossRef

15.

Pham NH, Baldo BA, Puy RM. Studies on the mechanism of multiple drug allergies. Structural basis of drug recognition. J Immunoassy Immunochem. 2001;22:47–73.CrossRef

16.

Cheong EY, Gottlieb T. Intravenous tigecycline in the treatment of severe recurrent Clostridium difficile colitis. Med J Aust. 2011;194:374–5.PubMed

17.

Herpers BL, Vlaminckx B, Burkhardt O, et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis. 2009;48:1732–5.PubMedCrossRef

18.

Lu CL, Liu CY, Liao CH, Huang YT, Wang HP, Hsueh PR. Severe and refractory Clostridium difficile infection successfully treated with tigecycline and metronidazole. Int J Antimicrob Agents. 2010;35:311–2.PubMedCrossRef

19.

El-Herte RI, Baban TA, Kanj SS. Recurrent refractory Clostridium difficile colitis treated successfully with rifaximin and tigecycline: a case report and review of the literature. Scand J Infect Dis. 2012;44:228–30.PubMedCrossRef

20.

Kopterides P, Papageorgiou C, Antoniadou A, et al. Failure of tigecycline to treat severe Clostridium difficile infection. Anaesth Intensive Care. 2010;38:755–8.PubMed

21.

Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis. 2012; 55 Suppl 2:S154–61. PubMedCrossRef

22.

Louie TJ, Cannon K, Byrne B, et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin re-expression and recurrence of CDI. Clin Infect Dis. 2012; 55 Suppl 2:S132–42. PubMedCrossRef

23.

Louie TJ, Emery J, Krulicki W, Byrne B, Mah M. OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection. Antimicrob Agents Chemother. 2009;53(1):261–3. PubMedCrossRef

24.

Nerandzic MM, Mullane K, Miller MA, Babakhani F, Donskey CJ. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin Infect Dis. 2012;55 Suppl 2:S121–6.PubMedCrossRef

25.

Al-Nassir WN, Sethi AK, Li Y, Pultz MJ, Riggs MM, Donskey CJ. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother. 2008;52(7):2403–6.PubMedCrossRef

26.

Liss BJ, Vehreschild JJ, Cornely OA, et al. Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. Infection. 2012. doi:10.1007/s15010-012-0269-y

Title: Severe anaphylaxis caused by orally administered vancomycin to a patient with Clostridium difficile infection
Authors: D. Bossé
C. Lemire
J. Ruel
A. M. Cantin
F. Ménard
L. Valiquette
Publication date: 01-04-2013
Publisher: Springer-Verlag
Published in: Infection / Issue 2/2013
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI: https://doi.org/10.1007/s15010-012-0328-4

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Severe anaphylaxis caused by orally administered vancomycin to a patient with Clostridium difficile infection

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2013

Souvenir from South Africa

Extrapulmonary mycobacterial infections in a cohort of HIV-positive patients: ultrasound experience from Vicenza, Italy

Erratum to: Multidisciplinary intensive care in extensive necrotizing fasciitis

Previous outpatient antibiotic use in patients admitted to hospital for COPD exacerbations: room for improvement

Survey of Klebsiella pneumoniae bacteraemia in two South Australian hospitals and detection of hypermucoviscous phenotype and magA/rmpA genotypes in K . pneumoniae isolates

Absence of liver steatosis in HIV–HCV co-infected patients receiving regimens containing tenofovir or abacavir

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page